Resonant Capital Advisors LLC Cuts Stock Position in Danaher Co. (NYSE:DHR)

Resonant Capital Advisors LLC lessened its holdings in Danaher Co. (NYSE:DHR) by 1.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,577 shares of the conglomerate’s stock after selling 143 shares during the period. Resonant Capital Advisors LLC’s holdings in Danaher were worth $3,778,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Tsfg LLC raised its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher in the 2nd quarter valued at $25,000. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter worth $25,000. Redmont Wealth Advisors LLC purchased a new stake in Danaher during the 1st quarter worth $30,000. Finally, MFA Wealth Advisors LLC purchased a new stake in Danaher during the 2nd quarter worth $51,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.9 %

NYSE DHR opened at $274.38 on Friday. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company has a 50-day simple moving average of $270.72 and a 200-day simple moving average of $260.02. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market capitalization of $203.23 billion, a PE ratio of 46.51, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. Danaher’s revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.05 EPS. On average, equities analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group lifted their price target on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Stifel Nicolaus lifted their price target on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. TD Cowen raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Leerink Partners raised their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 over the last ninety days. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.